NephroGenex Company Profile (NASDAQ:NRX)

About NephroGenex (NASDAQ:NRX)

NephroGenex logoNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NRX
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $0.40
  • 200 Day Moving Avg: $1.17
  • 52 Week Range: $0.10 - $8.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.08
  • P/E Growth: 0.0000
  • Average Volume: 288,621 shs.

Frequently Asked Questions for NephroGenex (NASDAQ:NRX)

What is NephroGenex's stock symbol?

NephroGenex trades on the NASDAQ under the ticker symbol "NRX."

How were NephroGenex's earnings last quarter?

NephroGenex Inc (NASDAQ:NRX) posted its quarterly earnings data on Wednesday, November, 11th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.12. View NephroGenex's Earnings History.

Where is NephroGenex's stock going? Where will NephroGenex's stock price be in 2017?

1 brokerages have issued twelve-month target prices for NephroGenex's shares. Their predictions range from $17.50 to $17.50. On average, they anticipate NephroGenex's share price to reach $17.50 in the next twelve months. View Analyst Ratings for NephroGenex.

Who are some of NephroGenex's key competitors?

How do I buy NephroGenex stock?

Shares of NephroGenex can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NephroGenex stock cost?

One share of NephroGenex stock can currently be purchased for approximately $0.14.

Analyst Ratings

Consensus Ratings for NephroGenex (NASDAQ:NRX) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.50 (12,391.08% upside)

Analysts' Ratings History for NephroGenex (NASDAQ:NRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/29/2017FBR & CoReiterated RatingOutperform$17.50LowView Rating Details
4/15/2016Rodman & RenshawReiterated RatingNeutralN/AView Rating Details
4/8/2016HC WainwrightDowngradeBuy -> NeutralN/AView Rating Details
8/17/2015MLV & Co.Reiterated RatingBuy$20.00N/AView Rating Details
(Data available from 5/22/2015 forward)


Earnings History for NephroGenex (NASDAQ:NRX)
Earnings by Quarter for NephroGenex (NASDAQ:NRX)
Earnings History by Quarter for NephroGenex (NASDAQ:NRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2015Q315($0.65)($0.53)ViewListenView Earnings Details
8/12/2015Q215($0.56)($0.72)ViewListenView Earnings Details
5/13/2015Q115($0.62)($0.58)ViewN/AView Earnings Details
3/24/2015Q414($0.58)($0.60)ViewN/AView Earnings Details
11/12/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014($0.24)($0.61)ViewN/AView Earnings Details
5/14/2014Q114($0.37)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NephroGenex (NASDAQ:NRX)
Current Year EPS Consensus Estimate: $-0.3000 EPS
Next Year EPS Consensus Estimate: $-1.7100 EPS


Dividend History for NephroGenex (NASDAQ:NRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for NephroGenex (NASDAQ:NRX)
Insider Trades by Quarter for NephroGenex (NASDAQ:NRX)
Insider Trades by Quarter for NephroGenex (NASDAQ:NRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/6/2015Ventures V L.P. RhoMajor ShareholderSell273,860$10.58$2,897,438.80View SEC Filing  
11/25/2014Bob PetersonVPBuy2,000$4.20$8,400.00View SEC Filing  
2/14/2014Robert R SeltzerDirectorBuy790,000$12.00$9,480,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NephroGenex (NASDAQ:NRX)
Latest Headlines for NephroGenex (NASDAQ:NRX)
DateHeadline logoNephroGenex (NRX) Getting Positive Media Coverage, Report Shows - April 27 at 5:22 PM logoNephroGenex (NRX) Getting Favorable Media Coverage, AlphaOne Reports - April 20 at 4:26 PM logoNaturex CEO Interview - FY 2016 Results (Video) - March 30 at 7:09 PM logoFBR & Co Reiterates "Outperform" Rating for NephroGenex Inc (NRX) - March 29 at 5:25 PM logo3 Companies Filed For Chapter 11 Bankruptcy Today - May 2 at 2:37 PM logoNephroGenex Files For Bankruptcy Protection Under Chapter 11 - May 2 at 9:43 AM logoResearch Triangle area's biotech sector in steep bear market - April 26 at 3:00 PM logoHow NephroGenex went from darling to disaster - April 14 at 4:30 PM logoNephroGenex downgraded by H.C. Wainwright - April 8 at 7:10 AM logoNATUREX - FY 2015 Results - March 31 at 2:46 AM logoNEPHROGENEX, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Costs Associated with Exit or D - February 24 at 4:31 PM logoHere's Why NephroGenex Plunged 40% On Wednesday - February 24 at 3:16 PM logoNephroGenex stock tumbles after announcement to halt trial over consideration of reverse merger - February 24 at 11:24 AM logoNephroGenex Provides Corporate Update - February 24 at 9:20 AM logoQ4 2015 NephroGenex Inc Earnings Release - After Market Close - February 24 at 7:07 AM logoNephroGenex to Host Conference Call and Webcast on Fourth Quarter and Full Year 2015 Financial Results on Thursday, February 25, 2016 - February 16 at 8:00 AM logoNephroGenex to Present at the 18th Annual BIO CEO & Investor Conference - Business Wire (press release) - January 27 at 1:43 PM logoAMGN Gets FDA Nod, Data Awaits RGLS In Feb, FORWARD Puts ALKS On The Back Foot - Nasdaq - January 22 at 8:38 PM logoPre-Open Stock Movers 01/22: (NRX) (EGHT) (CHK) Higher; (CSII) (LGCY) (DGII) Lower (more...) - - January 22 at 8:38 PM logoNephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin Phase 3 as Planned - January 22 at 8:38 PM logoNephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin ... - - January 21 at 8:49 PM logo4:11 pm NephroGenex announces independent DSMB recommendation to continue Phase 3 study of oral Pyridorin in diabetic nephropathy without modification - January 21 at 4:11 PM logoNEPHROGENEX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - January 7 at 4:03 PM logoNephroGenex to Participate in Two Healthcare Conferences in January - January 6 at 8:00 AM logoNephroGenex Announces Formation of Scientific Advisory Board - January 5 at 8:00 AM logoRaleigh drug developer sees shares soar on good news from FDA - December 14 at 5:40 PM logoThanks, FDA: NephroGenex Investors Rejoice After New Clearance - December 14 at 12:52 PM logoNephroGenex (NRX) Stock Soars After FDA Approves Clinical Trials for Kidney Treatment - December 14 at 11:29 AM logoNephroGenex Announces FDA Clearance of IND Application for Clinical Study of Intravenous Pyridorin in the Treatment of Acute Kidney Injury - December 14 at 8:00 AM logoNEPHROGENEX, INC. Financials - December 8 at 1:18 PM logoNEPHROGENEX, INC. Files SEC form 8-K, Financial Statements and Exhibits - November 13 at 7:14 AM


NephroGenex (NRX) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by Staff